11 – 20 of 20
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- next »
- 2011
-
Mark
Myeloablative allogeneic stem cell transplantation for lymphoblastic lymphoma in Sweden: A retrospective study.
(
- Contribution to journal › Letter
-
Mark
Long-term survival following allogeneic or syngeneic stem cell transplant for follicular lymphoma in Sweden.
(
- Contribution to journal › Article
-
Mark
T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
(
- Contribution to journal › Article
- 2010
-
Mark
Gene expression profiling and chromatin immunoprecipitation identify DBN1, SETMAR and HIG2 as direct targets of SOX11 in mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia
(
- Contribution to journal › Article
-
Mark
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
(
- Contribution to journal › Article
- 2008
-
Mark
Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden
(
- Contribution to journal › Article
-
Mark
Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma : growth inhibition by receptor activation
(
- Contribution to journal › Article
-
Mark
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group
(
- Contribution to journal › Article
-
Mark
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
(
- Contribution to journal › Article
- « previous
- 1
- 2
- next »